查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
心肌炎疾病市场报告：2030 年趋势、预测与竞争分析
市场调查报告书
商品编码
1356863

心肌炎疾病市场报告：2030 年趋势、预测与竞争分析

Myocarditis Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

心肌炎的趋势和预测

预计到 2030 年，全球心肌炎市场将达到 19.3 亿美元，2024 年至 2030 年年复合成长率为 5.6%。该市场的主要促进因素是慢性病患病的增加、医疗基础设施投资的增加以及老年人口的增加。全球心肌炎市场前景广阔，医院、专科诊所和居家医疗市场蕴藏商机。

心肌炎疾病依部位分类

该研究包括按类型、治疗方法、诊断、最终用途和地区对全球心肌炎疾病的预测。

心肌炎疾病相关企业名单

市场上的公司根据其提供的产品品质进行竞争。该市场的主要企业专注于扩大製造设施、投资研发、开拓基础设施以及利用整个价值链的整合机会。这些策略使心肌炎公司能够满足不断增长的需求，确保竞争力，开发创新产品和技术，降低製造成本，并扩大基本客群。本报告中涉及的心肌炎治疗药物的公司简介如下。

  • F·霍夫曼·拉罗什
  • 迈兰公司
  • 梯瓦製药工业公司
  • 赛诺菲
  • 辉瑞公司
  • 葛兰素史克
  • 诺华公司
  • 兹杜斯·卡迪拉
  • 阿斯利康
  • 强生公司

心肌炎疾病

  • Lucintel 预测，慢性心肌炎将在预测期内出现最高成长。
  • 医院仍然是最大的部分。
  • 由于心血管疾病患者数量的增加、医疗基础设施的持续发展以及老年人口的增加，预计亚太地区在预测期内将出现最高的增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要要素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球心肌炎疾病市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业促进因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球心肌炎疾病市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球心肌炎疾病市场
    • 急性心肌炎
    • 慢性心肌炎
    • 淋巴球性心肌炎
  • 按治疗分類的全球心肌炎疾病市场
    • 药品
    • 外科手术
    • 其他的
  • 全球心肌炎疾病市场（按诊断）
    • 验血
    • 影像检查
    • 心导管
    • 心肌切片检查
    • 其他的
  • 全球心肌炎疾病市场（依最终用途）
    • 医院
    • 专科诊所
    • 居家护理
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球心肌炎疾病市场（按地区）
  • 北美心肌炎疾病市场
  • 欧洲心肌炎疾病市场
  • 亚太心肌炎疾病市场
  • 其他区域性心肌炎疾病市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球心肌炎疾病市场成长机会
    • 全球心肌炎疾病治疗市场成长机会
    • 全球心肌炎疾病市场诊断成长机会
    • 全球心肌炎疾病市场成长机会（依最终用途）
    • 全球心肌炎疾病市场成长机会（按地区）
  • 全球心肌炎疾病市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球心肌炎疾病市场的产能扩张
    • 全球心肌炎疾病市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • F. Hoffmann-La Roche
  • Mylan NV
  • Teva Pharmaceutical Industries
  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Zydus Cadila
  • AstraZeneca
  • Johnson & Johnson
简介目录

Myocarditis Disease Trends and Forecast

The future of the global myocarditis disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global myocarditis disease market is expected to reach an estimated $1.93 billion by 2030 with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are increasing prevalence of chronic disorders, increasing investment for healthcare infrastructure ,and growing number of geriatric population.

A more than 150-page report is developed to help in your business decisions.

Myocarditis Disease by Segment

The study includes a forecast for the global myocarditis disease by type, treatment, diagnosis, end use, and region.

Myocarditis Disease Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Acute Myocarditis
  • Chronic Myocarditis
  • Lymphocytic Myocarditis

Myocarditis Disease Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery
  • Others

Myocarditis Disease Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Tests
  • Imaging Tests
  • Cardiac Catheterization
  • Heart Muscle Biopsy
  • Others

Myocarditis Disease Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Myocarditis Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Myocarditis Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myocarditis disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myocarditis disease companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Mylan N.V.
  • Teva Pharmaceutical Industries
  • Sanofi
  • Pfizer
  • Glaxosmithkline
  • Novartis
  • Zydus Cadila
  • Astrazeneca
  • Johnson & Johnson

Myocarditis Disease

  • Lucintel forecasts that chronic myocarditis is expected to witness highest growth over the forecast period.
  • Hospital will remain the largest segment.
  • APAC is expected to witness highest growth over the forecast period due to growing cases of cardiovascular diseases, on-going development of healthcare infrastructure, and rising geriatric population in this region.

Features of the Global Myocarditis Disease Market

  • Market Size Estimates: Myocarditis Disease Market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Myocarditis Disease Market by various segments, such as by type, treatment, diagnosis, end use and region in terms of($B).
  • Regional Analysis: Myocarditis Disease Market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, treatments, diagnosis, end uses, and region.s for the myocarditis disease market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myocarditis disease market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the myocarditis disease market size?

Answer: The global myocarditis disease market is expected to reach an estimated $1.93 billion by 2030.

Q.2. What is the growth forecast for myocarditis disease market?

Answer: The global myocarditis disease market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the myocarditis disease market?

Answer: The major drivers for this market are increasing prevalence of chronic disorders, increasing investment for healthcare infrastructure, and growing number of geriatric population .

Q.4. What are the major segments for myocarditis disease market?

Answer: The future of the myocarditis disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key myocarditis disease market companies?

Answer: Some of the key myocarditis disease companies are as follows:

  • F. Hoffmann-La Roche
  • Mylan N.V.
  • Teva Pharmaceutical Industries
  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Zydus Cadila
  • AstraZeneca
  • Johnson & Johnson

Q.6. Which myocarditis disease market segment will be the largest in future?

Answer: Lucintel forecasts that chronic myocarditis is expected to witness highest growth over the forecast period.

Q.7. In myocarditis disease market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing cases of cardiovascular diseases, on-going development of healthcare infrastructure, and rising geriatric population in this region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the myocarditis disease market by type (acute myocarditis, chronic myocarditis, and lymphocytic myocarditis), treatment (medication, surgery, and others), diagnosis (blood tests, imaging tests, cardiac catheterization, heart muscle biopsy, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Myocarditis Disease Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Myocarditis Disease Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Myocarditis Disease Market by Type
    • 3.3.1: Acute Myocarditis
    • 3.3.2: Chronic Myocarditis
    • 3.3.3: Lymphocytic Myocarditis
  • 3.4: Global Myocarditis Disease Market by Treatment
    • 3.4.1: Medication
    • 3.4.2: Surgery
    • 3.4.3: Others
  • 3.5: Global Myocarditis Disease Market by Diagnosis
    • 3.5.1: Blood Tests
    • 3.5.2: Imaging Tests
    • 3.5.3: Cardiac Catheterization
    • 3.5.4: Heart Muscle Biopsy
    • 3.5.5: Others
  • 3.6: Global Myocarditis Disease Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Homecare
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Myocarditis Disease Market by Region
  • 4.2: North American Myocarditis Disease Market
    • 4.2.4: North American Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Myocarditis Disease Market
    • 4.3.1: European Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
    • 4.3.2: European Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Myocarditis Disease Market
    • 4.4.1: APAC Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
    • 4.4.2: APAC Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Myocarditis Disease Market
    • 4.5.1: ROW Myocarditis Disease Market by Type: Acute Myocarditis, Chronic Myocarditis, and Lymphocytic Myocarditis
    • 4.5.2: ROW Myocarditis Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Myocarditis Disease Market by Type
    • 6.1.2: Growth Opportunities for the Global Myocarditis Disease Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Myocarditis Disease Market by Diagnosis
    • 6.1.4: Growth Opportunities for the Global Myocarditis Disease Market by End Use
    • 6.1.5: Growth Opportunities for the Global Myocarditis Disease Market by Region
  • 6.2: Emerging Trends in the Global Myocarditis Disease Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Myocarditis Disease Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Myocarditis Disease Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Mylan N.V.
  • 7.3: Teva Pharmaceutical Industries
  • 7.4: Sanofi
  • 7.5: Pfizer
  • 7.6: GlaxoSmithKline
  • 7.7: Novartis
  • 7.8: Zydus Cadila
  • 7.9: AstraZeneca
  • 7.10: Johnson & Johnson